Empath Ventures

Investment Context

This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.

Empath Ventures appears to be a specialist venture investor centered on psychedelic medicine and novel therapeutic approaches, with a public-facing thesis that extends into adjacent health technologies. Public profiles describe the firm as active in early-stage deals, with global reach and reported investment activity in the United States, the United Kingdom, and Australia. The firm is associated with founder Brom Rector, who has publicly discussed building an early-stage psychedelic venture fund and using a podcast to engage founders, investors, and operators across the space. Publicly surfaced portfolio references include psychedelic and adjacent health companies such as Psylo, Wavepaths, and Motif Neurotech.